Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Inventory (2016 - 2025)

Historic Inventory for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to $21.3 million.

  • Protalix BioTherapeutics' Inventory rose 2358.28% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 2358.28%. This contributed to the annual value of $21.2 million for FY2024, which is 1154.11% up from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Inventory is $21.3 million, which was up 2358.28% from $21.1 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Inventory high stood at $22.3 million for Q1 2024, and its period low was $13.6 million during Q2 2021.
  • Its 5-year average for Inventory is $18.4 million, with a median of $19.0 million in 2023.
  • Per our database at Business Quant, Protalix BioTherapeutics' Inventory skyrocketed by 4821.45% in 2023 and then tumbled by 2031.23% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Inventory (Quarter) stood at $18.0 million in 2021, then decreased by 6.41% to $16.8 million in 2022, then increased by 13.34% to $19.0 million in 2023, then increased by 11.54% to $21.2 million in 2024, then rose by 0.06% to $21.3 million in 2025.
  • Its last three reported values are $21.3 million in Q3 2025, $21.1 million for Q2 2025, and $19.5 million during Q1 2025.